3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Neoplasm Metastasis
10
Lung Neoplasms
9
Carcinoma, Medullary
9
Neoplasms
6
Thyroid Neoplasms
5
Glioma
5
Glioblastoma
5
Gliosarcoma
4
Colorectal Neoplasms
4
Brain Neoplasms
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Breast Neoplasms
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Rectal Neoplasms
2
Familial medullary thyroid carcinoma
2
Disease Progression
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Biliary Tract Neoplasms
2
Waldenstrom Macroglobulinemia
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Recurrence
1
Interventions
Gemcitabine
39
Cisplatin
24
Oxaliplatin
15
pembrolizumab
12
Capecitabine
12
Fluorouracil
9
Leucovorin
7
Albumin-Bound Paclitaxel
7
lenvatinib
6
Radiofrequency Ablation
6
Panitumumab
6
130-nm albumin-bound paclitaxel
6
Irinotecan
5
Bevacizumab
5
durvalumab
4
Taxes
4
Nivolumab
4
Hepatectomy
4
Drug Therapy
4
tremelimumab
3
apatinib
3
Radiosurgery
3
Platinum
3
Injections
3
Floxuridine
3
Cetuximab
3
1,2-diaminocyclohexaneplatinum II citrate
3
trametinib
2
spartalizumab
2
sintilimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Cholangiocarcinoma
×
vandetanib
×
Clear all
NCT00753675
2016-10-10
VANGOGH
Sanofi
Phase 2
Completed
174 enrolled
12 charts